Morgan Stanley Maintains Overweight on BeiGene, Lowers Price Target to $360
Morgan Stanley maintains BeiGene (NASDAQ:BGNE) with a Overweight and lowers the price target from $407 to $360.
Death Cross Looms Over BeiGene Investors
If history is any guide, there may be trouble ahead for shares of BeiGene (NASDAQ:BGNE). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1B
BeiGene Ltd (NASDAQ: BGNE)
46 Biggest Movers From Yesterday
Gainers
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday.
36 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.
Nanjing Leads Biolabs and BeiGene Announced Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China
BeiGene (NASDAQ: BGNE), a global science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and Nanjing Leads Biolabs, Inc.
BeiGene Presented Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at ASH 2021; Said BRUKINSA Demonstrated Superiority in Progression-free Survival Over Chemoimmunotherapy as a First-line Treatment for Pa…
BeiGene (NASDAQ: BGNE), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced results from a planned interim analysis of the Phase 3 SEQUOIA trial in patients with treatment-naïve (TN) chronic lym
BeiGene Unveils Results From Late-Stage Tislelizumab In Nasopharyngeal Cancer
BeiGene Ltd (NASDAQ: BGNE)